Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
Zsuzsanna H McMahanYannick AllanoreChristopher P DentonMasataka KuwanaMarco Matucci-CerinicJanet E PopeTatsuya AtsumiRadim BečvářLászló CzirjákEric HachullaTomonori IshiiOsamu IshikawaSindhu R JohnsonEllen De LangheChiara StagnaroValeria RiccieriElena SchiopuRichard M SilverVanessa SmithVirginia SteenWendy StevensGabriella SzücsMarie-Elise TruchetetMelanie WosnitzaKaisa LaapasJanethe de Oliveira PenaZhen YaoFrank KramerOliver DistlerPublished in: Annals of the rheumatic diseases (2020)
Riociguat did not significantly benefit mRSS versus placebo at the predefined p<0.05. Secondary and exploratory analyses showed potential efficacy signals that should be tested in further trials. Riociguat was well tolerated.